Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Todd Neale

January 12, 2024

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Daily News

FDA Alert: Possible Early Deterioration of Abbott Trifecta SAVR Valves

Todd Neale

February 27, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Daily News

FDA Investigating Possible Sex Differences in LAAO Outcomes

Todd Neale

September 27, 2021

News Daily News

Cardiology Societies Unite to Condemn Racism and Health Inequality

L.A. McKeown

June 01, 2020

News Conference News

ACC, EHRA Cancel 2020 Meetings Over COVID-19

Michael O'Riordan

March 09, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2019

Shelley Wood

May 01, 2019

News Daily News

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Michael O'Riordan

November 06, 2018

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

Alirocumab to Remain On Market While Companies Clash Over Patents

Michael O'Riordan

February 09, 2017

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

FDA Alert: Possible Early Deterioration of Abbott Trifecta SAVR Valves

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

A Simple Nudge Moves the Needle on Statin Prescribing

FDA Investigating Possible Sex Differences in LAAO Outcomes

Cardiology Societies Unite to Condemn Racism and Health Inequality

ACC, EHRA Cancel 2020 Meetings Over COVID-19

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

TCTMD’s Top 10 Most Popular Stories for April 2019

SORT-OUT IX: Statistical Mix-up Turns Trial’s Primary Endpoint Around

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Alirocumab to Remain On Market While Companies Clash Over Patents

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content